We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accenture, Merck & Amazon AWS Partner for Cloud Platform
Read MoreHide Full Article
Accenture plc (ACN - Free Report) , Merck (MRK - Free Report) and Amazon’s (AMZN - Free Report) Amazon Web Services (“AWS”) have collaborated to develop a cloud-based informatics research platform.
Built on AWS, this platform is one of the solutions that Accenture Applied Life Sciences Solutions practice offers. Notably, Merck is the first pharmaceutical to use it.
The platform enables scientific research-based organizations in the life sciences industry to quickly access, aggregate and analyze research data from multiple applications. Data can now be accessed from a single interface, with integrated workflow, reporting and analytics capabilities. It facilitates easier collaboration across the R&D enterprise, including external partners, through incorporation of a modern user interface and a secure, multi-tenant environment.
The platform can be availed by a range of life sciences industry players such as pharmaceutical, biotech and scientific research organizations to enhance productivity, efficiency and innovation in the early stages of drug development.
Also, Accenture will form a coalition of clients to oversee and expand capabilities of the platform, opening up an opportunity for pre-competitive collaboration.
Brad Michel, managing director of Accenture Scientific Informatics Services, stated that “understanding the industry’s need to drive faster, more efficient and more innovative scientific research, we are pleased to collaborate with Merck and AWS to launch the platform and associated ecosystem to help our clients accelerate the discovery of new, targeted treatments for patients.”
In a year’s time, shares of Accenture have gained 25.6%, outperforming the S&P 500’s 15.8% rally.
Our Take
We believe that the latest move will help Accenture boost its Products segment as it comprises the Life Sciences industry group, which serves pharmaceutical, medical technology and biotechnology companies. Performance of this segment was particularly strong in the last reported quarter, with revenues increasing 17% on a year-over-year basis.
CRA International delivered an average four-quarter positive earnings surprise of 38.6%.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Accenture, Merck & Amazon AWS Partner for Cloud Platform
Accenture plc (ACN - Free Report) , Merck (MRK - Free Report) and Amazon’s (AMZN - Free Report) Amazon Web Services (“AWS”) have collaborated to develop a cloud-based informatics research platform.
Built on AWS, this platform is one of the solutions that Accenture Applied Life Sciences Solutions practice offers. Notably, Merck is the first pharmaceutical to use it.
The platform enables scientific research-based organizations in the life sciences industry to quickly access, aggregate and analyze research data from multiple applications. Data can now be accessed from a single interface, with integrated workflow, reporting and analytics capabilities. It facilitates easier collaboration across the R&D enterprise, including external partners, through incorporation of a modern user interface and a secure, multi-tenant environment.
The platform can be availed by a range of life sciences industry players such as pharmaceutical, biotech and scientific research organizations to enhance productivity, efficiency and innovation in the early stages of drug development.
Also, Accenture will form a coalition of clients to oversee and expand capabilities of the platform, opening up an opportunity for pre-competitive collaboration.
Brad Michel, managing director of Accenture Scientific Informatics Services, stated that “understanding the industry’s need to drive faster, more efficient and more innovative scientific research, we are pleased to collaborate with Merck and AWS to launch the platform and associated ecosystem to help our clients accelerate the discovery of new, targeted treatments for patients.”
In a year’s time, shares of Accenture have gained 25.6%, outperforming the S&P 500’s 15.8% rally.
Our Take
We believe that the latest move will help Accenture boost its Products segment as it comprises the Life Sciences industry group, which serves pharmaceutical, medical technology and biotechnology companies. Performance of this segment was particularly strong in the last reported quarter, with revenues increasing 17% on a year-over-year basis.
Accenture PLC Revenue (TTM)
Accenture PLC Revenue (TTM) | Accenture PLC Quote
Zacks Rank and Key Pick
Currently, Accenture carries a Zacks Rank #3 (Hold). A better-ranked stock in the broader Business Services Sector is CRA International (CRAI - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CRA International delivered an average four-quarter positive earnings surprise of 38.6%.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>